ArticleFrontiers in endocrinology2026
Elevated serum cystatin C predicts tophus formation in gout: evidence from a cross-sectional study.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the association between serum cystatin C (CysC) levels and tophus presence, and to assess its diagnostic value for structural joint damage in gout. Methods: In this cross-sectional study of 598 gout patients, we examined the association between serum CysC and both the presence and burden of tophi. The predictive value of CysC for tophus and bone erosion was further evaluated using logistic regression and ROC curve analyses. Results: Elevated serum CysC levels were significantly associated with older age, longer disease duration, and an increased prevalence of tophus, bone erosion, and the patients in the highest quartile (Q4, >1.28 mg/L) had a 3.87-fold higher adjusted odds of tophus (P < 0.05), showing a significant dose-response trend (P for trend = 0.003). Serum CysC alone demonstrated a moderate predictive value for tophus (AUC = 0.627), which improved in multivariable models (AUC = 0.777). A similar enhancement in predictive performance was noted for bone erosion (fully adjusted AUC, 0.756). There was a significant interaction between serum CysC and magnesium regarding tophus risk (P < 0.001). Furthermore, multivariate ordinal regression analysis identified higher CysC, longer gout duration, bone erosion, and the double contour sign as independent predictors of tophus burden. Conclusion: Serum CysC independently predicts tophus in gout and shows interaction with serum magnesium. Its integration into risk assessment may improve clinical stratification and support timely, individualized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.